Latest Breaking News On - Gilead sciences inc - Page 17 : comparemela.com

Gilead s Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch

Gilead s Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Gilead sciences incCymabay therapeutics inc

Gilead (GILD) Announces Positive Interim Results on PBC Drug

Gilead Sciences (GILD) experimental candidate, seladelpar, demonstrates significant improvements in liver disease progression and reduced itching in primary biliary cholangitis study.

Gilead sciences incZacks investment researchLigand pharmaceuticalsImage sourceZacks investmentGilead sciencesPharmaceutical ocalivaZacks rankStrong sellStrong buyZacks consensus estimate

Gilead Sciences - Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis

FOSTER CITY - Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with.

United kingdomFoster cityUnited statesMerdad parseyJacquie rossMeaghan smithGilead companyCymabay therapeutics incGilead sciences in liver diseaseGilead sciencesRegulatory agencyGilead sciences incUniversity of miamiExchange commissionDrug administrationEuropean medicines agency

Cornerstone Advisors LLC Decreases Stock Holdings in Gilead Sciences, Inc (NASDAQ:GILD)

Cornerstone Advisors LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 26.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,700 shares of the biopharmaceutical company’s stock after selling 23,500 shares during the quarter. Cornerstone Advisors LLC’s […]

United statesMerdad parseyComplera evipleraQuarter for gilead sciencesPrincipal financial group incGilead sciencesTokio marine asset management coMorgan stanleyGilead sciences incSecurities exchange commissionLife insurance company ltdCornerstone advisorsGilead sciences dividend announcementCantor fitzgeraldGilead sciences stock performanceNews ratings for gilead sciences daily

Verity Asset Management Inc Acquires 168 Shares of Gilead Sciences, Inc (NASDAQ:GILD)

Verity Asset Management Inc. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,731 shares of the biopharmaceutical company’s stock after buying an additional 168 shares during the quarter. Verity Asset […]

United statesMerdad parseyComplera evipleraGilead sciences company profileNews ratings for gilead sciences dailyWealth management groupQuarter for gilead sciencesMaxim groupGilead sciences incTompkins financial corpMorgan stanleyGilead sciencesGilead sciences dividend announcementRakuten securities incSecurities exchange commissionFortitude family office